More than 15 million people in the United States, in the United Kingdom, Germany And France does not know that they have the most aggressive form of hepatic steatosis, according to research.
Hepatic steatotic disease associated with metabolic dysfunction – the formal name for a non -alcoholic liver disease – occurs in people who do not drink or minimal alcohol quantities whose liver contains more than 5% fat.
It is believed that about two -thirds of patients with type 2 diabetes have the condition, which is also associated with obesity, heart and circulatory diseases.
About 5% of adults in the world have the most aggressive form of Masld. Steathepatitis associated with metabolic dysfunction (puree) causes fibrosis (scars) and can cause cirrhosis and is linked to a greater risk of cardiovascular disease, chronic kidney disease and liver cancer.
But the vast majority of people do not know they have the condition. An international group of researchers has examined the prevalence and diagnosis of an aggressive liver disease in the United States, the United Kingdom, Germany and France.
Researchers found that little less than 3% of people in the United Kingdom, France and Germany, and that 4% of those in the United States have a puree, but diagnostic rates were less than 18%. This means that around 20 million people in the United States, the United Kingdom, Germany and France live with Mash, but only 2.5 million people have a diagnosis, leaving more than three quarters – around 16.7 million people – ignoring that they have the condition.
THE Report, published in Lancet Regional Health Europe and presented at the Global Thinktank meeting on Steatotic liver disease In Barcelona, Spain, Thursday, calls for double the diagnostic rates of 2022 levels. Traditionally, puree has been diagnosed by biopsy, but now non -invasive methods such as blood tests, MRI ultrasounds and analyzes can be used. Consequently, everyone has type 2 diabetes; obesity combined with one or more other risk factors; And those who have constantly high liver enzymes must be projected for puree, conclude the researchers.
Dr. Jeffrey Lazarus, the main author of the newspaper and world health teacher in New York and Barcelona, said: “The undiagnosed puree cost of billions of books in loss of productivity and bad health. Unless diagnostic rates are doubled, in parallel with similar increases in treatment and care, direct health costs are predicted to triple in the next 20 years. “
Responding to the conclusions, Emmanouil Tsochatzis, professor of hepatology at the University College of London and hepatologist consulting at the Royal Free Hospital, said: “More than 15 million people in the United States and Europe have the deadliest form of fatty liver disease – and do not know. Without faster diagnosis and access to treatment, human and economical toll -”.
Research has also caused renewed calls for the use of weight loss jabs to treat puree.
Dr. Paul Brennan, co-author of the Journal Lancet and hepatologist at the NHS Tayside, said: “The GLP-1 (including Wegovy and Mounjaro) offer the potential to resynchronize our metabolism, by introducing feelings of satiety-and delaying the time that the stomach takes to empty the packages, which results from the reduction of the intimate, and Improvements, the packages reduced in a reduction in intimate calière, and improvements, disabilities are often resulting from intimate calière, and improvements in weight loss arrangement, thus reducing the formation of scar tissue in the liver. »»
Michael Betel, the president of the fat alliance Liver Alliance, said: “Too many people living with type 2 diabetes or obesity are never tested for Mash until it is too late. We need a huge increase in liver health assessments in patients living with these diseases. testing Suggest that they could benefit from several metabolic conditions and improve our liver health. »»
Separately a study On Wednesday, published Wednesday, the Dapagliflozine of diabetes, which reduces blood sugar, can also reduce fat levels and fibrosis in the liver.
